-
2
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
[PMID: 11784875]
-
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98 [PMID: 11784875 DOI: 10.1056/NEJMoa011954]
-
(2002)
N Engl J Med
, vol.346
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
Langer, C.4
Sandler, A.5
Krook, J.6
Zhu, J.7
Johnson, D.H.8
-
3
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
[PMID: 20525992]
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 [PMID: 20525992 DOI: 10.1056/NEJMoa1003466]
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
Akerley, W.11
Van Den Eertwegh, A.J.12
Lutzky, J.13
Lorigan, P.14
Vaubel, J.M.15
Linette, G.P.16
Hogg, D.17
Ottensmeier, C.H.18
Lebbé, C.19
Peschel, C.20
Quirt, I.21
Clark, J.I.22
Wolchok, J.D.23
Weber, J.S.24
Tian, J.25
Yellin, M.J.26
Nichol, G.M.27
Hoos, A.28
Urba, W.J.29
more..
-
4
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
[PMID: 20818862]
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422 [PMID: 20818862 DOI: 10.1056/NEJMoa1001294]
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
Redfern, C.H.7
Ferrari, A.C.8
Dreicer, R.9
Sims, R.B.10
Xu, Y.11
Frohlich, M.W.12
Schellhammer, P.F.13
-
5
-
-
79953151458
-
Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion
-
[PMID: 21436444]
-
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570 [PMID: 21436444 DOI: 10.1126/science.1203486331/6024/1565]
-
(2011)
Science
, vol.331
, pp. 1565-1570
-
-
Schreiber, R.D.1
Old, L.J.2
Smyth, M.J.3
-
6
-
-
80053222721
-
Developing effective cancer vaccines
-
[PMID: 21944017]
-
Baxevanis CN, Perez SA, Papamichail M. Developing effective cancer vaccines. Eur J Cancer 2011; 47 Suppl 3: S364-S365 [PMID: 21944017 DOI: 10.1016/S0959-8049(11)70205-2]
-
(2011)
Eur J Cancer
, vol.47
, pp. S364-S365
-
-
Baxevanis, C.N.1
Perez, S.A.2
Papamichail, M.3
-
7
-
-
31444439350
-
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
-
[PMID: 16421594]
-
Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-280 [PMID: 16421594]
-
(2006)
Br J Cancer
, vol.94
, pp. 275-280
-
-
Hiraoka, K.1
Miyamoto, M.2
Cho, Y.3
Suzuoki, M.4
Oshikiri, T.5
Nakakubo, Y.6
Itoh, T.7
Ohbuchi, T.8
Kondo, S.9
Katoh, H.10
-
8
-
-
53149083361
-
Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer
-
[PMID: 18671239]
-
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113: 1387-1395 [PMID: 18671239 DOI: 10.1002/cncr.23712]
-
(2008)
Cancer
, vol.113
, pp. 1387-1395
-
-
Kawai, O.1
Ishii, G.2
Kubota, K.3
Murata, Y.4
Naito, Y.5
Mizuno, T.6
Aokage, K.7
Saijo, N.8
Nishiwaki, Y.9
Gemma, A.10
Kudoh, S.11
Ochiai, A.12
-
9
-
-
77951877847
-
Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer
-
[PMID: 20234320]
-
Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010; 5: 585-590 [PMID: 20234320 DOI: 10.1097/JTO.0b013e3181d60fd7]
-
(2010)
J Thorac Oncol
, vol.5
, pp. 585-590
-
-
Shimizu, K.1
Nakata, M.2
Hirami, Y.3
Yukawa, T.4
Maeda, A.5
Tanemoto, K.6
-
10
-
-
84881458660
-
Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma
-
[PMID: 23851682]
-
Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Lau J, Jablons DM, Coussens LM. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 2013; 191: 2009-2017 [PMID: 23851682 DOI: 10.4049/jimmunol.1301317]
-
(2013)
J Immunol
, vol.191
, pp. 2009-2017
-
-
Ganesan, A.P.1
Johansson, M.2
Ruffell, B.3
Yagui-Beltrán, A.4
Lau, J.5
Jablons, D.M.6
Coussens, L.M.7
-
11
-
-
83555173668
-
Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways
-
[PMID: 21959954]
-
Yao M, Zhang W, Zhang Q, Xing L, Xu A, Liu Q, Cui B. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways. Lung 2011; 189: 453-460 [PMID: 21959954 DOI: 10.1007/s00408-011-9327-y]
-
(2011)
Lung
, vol.189
, pp. 453-460
-
-
Yao, M.1
Zhang, W.2
Zhang, Q.3
Xing, L.4
Xu, A.5
Liu, Q.6
Cui, B.7
-
12
-
-
0034789572
-
Phase i study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer
-
discussion 58 [PMID: 14656392]
-
Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, Longenecker M. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001; 3: 49-57; discussion 58 [PMID: 14656392]
-
(2001)
Clin Lung Cancer
, vol.3
, pp. 49-57
-
-
Palmer, M.1
Parker, J.2
Modi, S.3
Butts, C.4
Smylie, M.5
Meikle, A.6
Kehoe, M.7
MacLean, G.8
Longenecker, M.9
-
13
-
-
27244449289
-
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer
-
[PMID: 16170175]
-
Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23: 6674-6681 [PMID: 16170175]
-
(2005)
J Clin Oncol
, vol.23
, pp. 6674-6681
-
-
Butts, C.1
Murray, N.2
Maksymiuk, A.3
Goss, G.4
Marshall, E.5
Soulières, D.6
Cormier, Y.7
Ellis, P.8
Price, A.9
Sawhney, R.10
Davis, M.11
Mansi, J.12
Smith, C.13
Vergidis, D.14
Ellis, P.15
MacNeil, M.16
Palmer, M.17
-
14
-
-
0029787977
-
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
-
[PMID: 8877724]
-
MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996; 19: 309-316 [PMID: 8877724]
-
(1996)
J Immunother Emphasis Tumor Immunol
, vol.19
, pp. 309-316
-
-
MacLean, G.D.1
Miles, D.W.2
Rubens, R.D.3
Reddish, M.A.4
Longenecker, B.M.5
-
15
-
-
80054742888
-
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial
-
[PMID: 21744082]
-
Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Beier F, Falk M, Murray N. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011; 137: 1337-1342 [PMID: 21744082 DOI: 10.1007/s00432-011-1003-3]
-
(2011)
J Cancer Res Clin Oncol
, vol.137
, pp. 1337-1342
-
-
Butts, C.1
Maksymiuk, A.2
Goss, G.3
Soulières, D.4
Marshall, E.5
Cormier, Y.6
Ellis, P.M.7
Price, A.8
Sawhney, R.9
Beier, F.10
Falk, M.11
Murray, N.12
-
16
-
-
84891373760
-
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III nonsmall-cell lung cancer (START): A randomised, double-blind, phase 3 trial
-
[PMID: 24331154]
-
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III nonsmall-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 59-68 [PMID: 24331154 DOI: 10.1016/S1470-2045(13)70510-2]
-
(2014)
Lancet Oncol
, vol.15
, pp. 59-68
-
-
Butts, C.1
Socinski, M.A.2
Mitchell, P.L.3
Thatcher, N.4
Havel, L.5
Krzakowski, M.6
Nawrocki, S.7
Ciuleanu, T.E.8
Bosquée, L.9
Trigo, J.M.10
Spira, A.11
Tremblay, L.12
Nyman, J.13
Ramlau, R.14
Wickart-Johansson, G.15
Ellis, P.16
Gladkov, O.17
Pereira, J.R.18
Eberhardt, W.E.19
Helwig, C.20
Schröder, A.21
Shepherd, F.A.22
more..
-
19
-
-
33644912878
-
A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells
-
[PMID: 16446550]
-
Miyagawa N, Kono K, Mimura K, Omata H, Sugai H, Fujii H. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Oncology 2006; 70: 54-62 [PMID: 16446550]
-
(2006)
Oncology
, vol.70
, pp. 54-62
-
-
Miyagawa, N.1
Kono, K.2
Mimura, K.3
Omata, H.4
Sugai, H.5
Fujii, H.6
-
20
-
-
0033693387
-
A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes
-
[PMID: 11103782]
-
Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000; 60: 6272-6275 [PMID: 11103782]
-
(2000)
Cancer Res
, vol.60
, pp. 6272-6275
-
-
Schultz, E.S.1
Lethé, B.2
Cambiaso, C.L.3
Van Snick, J.4
Chaux, P.5
Corthals, J.6
Heirman, C.7
Thielemans, K.8
Boon, T.9
Van Der Bruggen, P.10
-
21
-
-
0037341162
-
MAGE-6 encodes HLA-DRbeta1∗0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma
-
[PMID: 12631591]
-
Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL, Kirkwood JM, Storkus WJ. MAGE-6 encodes HLA-DRbeta1∗0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003; 9: 947-954 [PMID: 12631591]
-
(2003)
Clin Cancer Res
, vol.9
, pp. 947-954
-
-
Tatsumi, T.1
Kierstead, L.S.2
Ranieri, E.3
Gesualdo, L.4
Schena, F.P.5
Finke, J.H.6
Bukowski, R.M.7
Brusic, V.8
Sidney, J.9
Sette, A.10
Logan, T.F.11
Kasamon, Y.L.12
Slingluff, C.L.13
Kirkwood, J.M.14
Storkus, W.J.15
-
22
-
-
0028050181
-
Structure, chromosomal localization, and expression of 12 genes of the MAGE family
-
[PMID: 7927540]
-
De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40: 360-369 [PMID: 7927540]
-
(1994)
Immunogenetics
, vol.40
, pp. 360-369
-
-
De Plaen, E.1
Arden, K.2
Traversari, C.3
Gaforio, J.J.4
Szikora, J.P.5
De Smet, C.6
Brasseur, F.7
Van Der Bruggen, P.8
Lethé, B.9
Lurquin, C.10
-
23
-
-
0028952240
-
BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
-
[PMID: 7895173]
-
Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2: 167-175 [PMID: 7895173]
-
(1995)
Immunity
, vol.2
, pp. 167-175
-
-
Boël, P.1
Wildmann, C.2
Sensi, M.L.3
Brasseur, R.4
Renauld, J.C.5
Coulie, P.6
Boon, T.7
Van Der Bruggen, P.8
-
24
-
-
28144457350
-
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
-
[PMID: 16299236]
-
Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-8062 [PMID: 16299236]
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8055-8062
-
-
Gure, A.O.1
Chua, R.2
Williamson, B.3
Gonen, M.4
Ferrera, C.A.5
Gnjatic, S.6
Ritter, G.7
Simpson, A.J.8
Chen, Y.T.9
Old, L.J.10
Altorki, N.K.11
-
25
-
-
84880755387
-
Adjuvant MAGE-A3 immunotherapy in resected non-smallcell lung cancer: Phase II randomized study results
-
[PMID: 23715567]
-
Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG. Adjuvant MAGE-A3 immunotherapy in resected non-smallcell lung cancer: phase II randomized study results. J Clin Oncol 2013; 31: 2396-2403 [PMID: 23715567 DOI: 10.1200/JCO.2012.43.7103]
-
(2013)
J Clin Oncol
, vol.31
, pp. 2396-2403
-
-
Vansteenkiste, J.1
Zielinski, M.2
Linder, A.3
Dahabreh, J.4
Gonzalez, E.E.5
Malinowski, W.6
Lopez-Brea, M.7
Vanakesa, T.8
Jassem, J.9
Kalofonos, H.10
Perdeus, J.11
Bonnet, R.12
Basko, J.13
Janilionis, R.14
Passlick, B.15
Treasure, T.16
Gillet, M.17
Lehmann, F.F.18
Brichard, V.G.19
-
27
-
-
18344390418
-
ERBB receptors and cancer: The complexity of targeted inhibitors
-
[PMID: 15864276]
-
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354 [PMID: 15864276]
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 341-354
-
-
Hynes, N.E.1
Lane, H.A.2
-
28
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
[PMID: 22285168]
-
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246 [PMID: 22285168 DOI: 10.1016/S1470-2045(11)70393-X]
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
Vergnenegre, A.4
Massuti, B.5
Felip, E.6
Palmero, R.7
Garcia-Gomez, R.8
Pallares, C.9
Sanchez, J.M.10
Porta, R.11
Cobo, M.12
Garrido, P.13
Longo, F.14
Moran, T.15
Insa, A.16
De Marinis, F.17
Corre, R.18
Bover, I.19
Illiano, A.20
Dansin, E.21
De Castro, J.22
Milella, M.23
Reguart, N.24
Altavilla, G.25
Jimenez, U.26
Provencio, M.27
Moreno, M.A.28
Terrasa, J.29
Muñoz-Langa, J.30
Valdivia, J.31
Isla, D.32
Domine, M.33
Molinier, O.34
Mazieres, J.35
Baize, N.36
Garcia-Campelo, R.37
Robinet, G.38
Rodriguez-Abreu, D.39
Lopez-Vivanco, G.40
Gebbia, V.41
Ferrera-Delgado, L.42
Bombaron, P.43
Bernabe, R.44
Bearz, A.45
Artal, A.46
Cortesi, E.47
Rolfo, C.48
Sanchez-Ronco, M.49
Drozdowskyj, A.50
Queralt, C.51
De Aguirre, I.52
Ramirez, J.L.53
Sanchez, J.J.54
Molina, M.A.55
Taron, M.56
Paz-Ares, L.57
more..
-
29
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
-
[PMID: 21783417]
-
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742 [PMID: 21783417 DOI: 10.1016/S1470-2045(11)70184-X]
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
Feng, J.4
Liu, X.Q.5
Wang, C.6
Zhang, S.7
Wang, J.8
Zhou, S.9
Ren, S.10
Lu, S.11
Zhang, L.12
Hu, C.13
Hu, C.14
Luo, Y.15
Chen, L.16
Ye, M.17
Huang, J.18
Zhi, X.19
Zhang, Y.20
Xiu, Q.21
Ma, J.22
Zhang, L.23
You, C.24
more..
-
30
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
[PMID: 19692680]
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957 [PMID: 19692680 DOI: 10.1056/NEJMoa0810699]
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
Sunpaweravong, P.7
Han, B.8
Margono, B.9
Ichinose, Y.10
Nishiwaki, Y.11
Ohe, Y.12
Yang, J.J.13
Chewaskulyong, B.14
Jiang, H.15
Duffield, E.L.16
Watkins, C.L.17
Armour, A.A.18
Fukuoka, M.19
-
31
-
-
33644656786
-
Treatment of NSCLC patients with an EGF-based cancer vaccine: Report of a Phase i trial
-
[PMID: 16357522]
-
Ramos TC, Vinageras EN, Ferrer MC, Verdecia BG, Rupalé IL, Pérez LM, Marinello GG, Rodríguez RP, Dávila AL. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther 2006; 5: 145-149 [PMID: 16357522]
-
(2006)
Cancer Biol Ther
, vol.5
, pp. 145-149
-
-
Ramos, T.C.1
Vinageras, E.N.2
Ferrer, M.C.3
Verdecia, B.G.4
Rupalé, I.L.5
Pérez, L.M.6
Marinello, G.G.7
Rodríguez, R.P.8
Dávila, A.L.9
-
32
-
-
38949193901
-
Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
-
[PMID: 18245547]
-
García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008; 14: 840-846 [PMID: 18245547 DOI: 10.1158/1078-0432.CCR-07-1050]
-
(2008)
Clin Cancer Res
, vol.14
, pp. 840-846
-
-
García, B.1
Neninger, E.2
De La Torre, A.3
Leonard, I.4
Martínez, R.5
Viada, C.6
González, G.7
Mazorra, Z.8
Lage, A.9
Crombet, T.10
-
34
-
-
0348223787
-
Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
-
[PMID: 14676299]
-
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, Mc-Grady G, Wahl SM. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886 [PMID: 14676299 DOI: 10.1084/jem.20030152]
-
(2003)
J Exp Med
, vol.198
, pp. 1875-1886
-
-
Chen, W.1
Jin, W.2
Hardegen, N.3
Lei, K.J.4
Li, L.5
Marinos, N.6
Mc-Grady, G.7
Wahl, S.M.8
-
35
-
-
0033229730
-
Plasma transforming growth factor-beta1 level before radio-therapy correlates with long term outcome of patients with lung carcinoma
-
[PMID: 10547543]
-
Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radio-therapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999; 86: 1712-1719 [PMID: 10547543]
-
(1999)
Cancer
, vol.86
, pp. 1712-1719
-
-
Kong, F.1
Jirtle, R.L.2
Huang, D.H.3
Clough, R.W.4
Anscher, M.S.5
-
36
-
-
33750586798
-
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
-
[PMID: 16966690]
-
Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4721-4730 [PMID: 16966690]
-
(2006)
J Clin Oncol
, vol.24
, pp. 4721-4730
-
-
Nemunaitis, J.1
Dillman, R.O.2
Schwarzenberger, P.O.3
Senzer, N.4
Cunningham, C.5
Cutler, J.6
Tong, A.7
Kumar, P.8
Pappen, B.9
Hamilton, C.10
DeVol, E.11
Maples, P.B.12
Liu, L.13
Chamberlin, T.14
Shawler, D.L.15
Fakhrai, H.16
-
37
-
-
67651091694
-
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
-
[PMID: 19287371]
-
Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009; 16: 620-624 [PMID: 19287371 DOI: 10.1038/cgt.2009.15]
-
(2009)
Cancer Gene Ther
, vol.16
, pp. 620-624
-
-
Nemunaitis, J.1
Nemunaitis, M.2
Senzer, N.3
Snitz, P.4
Bedell, C.5
Kumar, P.6
Pappen, B.7
Maples, P.B.8
Shawler, D.9
Fakhrai, H.10
-
40
-
-
65349083187
-
Negative regulators of T-cell activation: Potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
-
[PMID: 19426215]
-
Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229: 67-87 [PMID: 19426215 DOI: 10.1111/j.1600-065X.2009.00763.x]
-
(2009)
Immunol Rev
, vol.229
, pp. 67-87
-
-
Pentcheva-Hoang, T.1
Corse, E.2
Allison, J.P.3
-
41
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
[PMID: 22658127]
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454 [PMID: 22658127 DOI: 10.1056/NEJMoa1200690]
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
Powderly, J.D.7
Carvajal, R.D.8
Sosman, J.A.9
Atkins, M.B.10
Leming, P.D.11
Spigel, D.R.12
Antonia, S.J.13
Horn, L.14
Drake, C.G.15
Pardoll, D.M.16
Chen, L.17
Sharfman, W.H.18
Anders, R.A.19
Taube, J.M.20
McMiller, T.L.21
Xu, H.22
Korman, A.J.23
Jure-Kunkel, M.24
Agrawal, S.25
McDonald, D.26
Kollia, G.D.27
Gupta, A.28
Wigginton, J.M.29
Sznol, M.30
more..
-
42
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
[PMID: 22658128]
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465 [PMID: 22658128 DOI: 10.1056/NEJMoa1200694]
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
Drake, C.G.7
Camacho, L.H.8
Kauh, J.9
Odunsi, K.10
Pitot, H.C.11
Hamid, O.12
Bhatia, S.13
Martins, R.14
Eaton, K.15
Chen, S.16
Salay, T.M.17
Alaparthy, S.18
Grosso, J.F.19
Korman, A.J.20
Parker, S.M.21
Agrawal, S.22
Goldberg, S.M.23
Pardoll, D.M.24
Gupta, A.25
Wigginton, J.M.26
more..
-
43
-
-
55949083407
-
Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment
-
[PMID: 18838703]
-
Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283 [PMID: 18838703 DOI: 10.1200/JCO.2008.17.8954]
-
(2008)
J Clin Oncol
, vol.26
, pp. 5275-5283
-
-
Fong, L.1
Small, E.J.2
-
44
-
-
84863911486
-
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study
-
[PMID: 22547592]
-
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-2054 [PMID: 22547592 DOI: 10.1200/JCO.2011.38.4032]
-
(2012)
J Clin Oncol
, vol.30
, pp. 2046-2054
-
-
Lynch, T.J.1
Bondarenko, I.2
Luft, A.3
Serwatowski, P.4
Barlesi, F.5
Chacko, R.6
Sebastian, M.7
Neal, J.8
Lu, H.9
Cuillerot, J.M.10
Reck, M.11
-
45
-
-
0033811566
-
Paclitaxel (175 mg/m2) plus carboplatin (6 auc) versus paclitaxel (225 mg/m2) plus carboplatin (6 auc) in advanced non-smallcell lung cancer (NSCLC): A multicenter randomized trial hellenic cooperative oncology group (hecog)
-
[PMID: 10997806]
-
Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C, Kalophonos C, Pavlidis N, Nikolaidis C, Papaconstantinou C, Fountzilas G. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-smallcell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000; 11: 799-805 [PMID: 10997806]
-
(2000)
Ann Oncol
, vol.11
, pp. 799-805
-
-
Kosmidis, P.1
Mylonakis, N.2
Skarlos, D.3
Samantas, E.4
Dimopoulos, M.5
Papadimitriou, C.6
Kalophonos, C.7
Pavlidis, N.8
Nikolaidis, C.9
Papaconstantinou, C.10
Fountzilas, G.11
-
46
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
[PMID: 19934295]
-
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420 [PMID: 19934295 DOI: 10.1158/1078-0432.CCR-09-1624]
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
Weber, J.S.4
Hamid, O.5
Lebbé, C.6
Maio, M.7
Binder, M.8
Bohnsack, O.9
Nichol, G.10
Humphrey, R.11
Hodi, F.S.12
-
47
-
-
78449244037
-
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
-
[PMID: 21074065]
-
Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507 [PMID: 21074065 DOI: 10.1053/j.seminoncol.2010.09.007]
-
(2010)
Semin Oncol
, vol.37
, pp. 499-507
-
-
Di Giacomo, A.M.1
Biagioli, M.2
Maio, M.3
-
51
-
-
84255197842
-
Cancer immunotherapy comes of age
-
[PMID: 22193102]
-
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489 [PMID: 22193102 DOI: 10.1038/nature10673]
-
(2011)
Nature
, vol.480
, pp. 480-489
-
-
Mellman, I.1
Coukos, G.2
Dranoff, G.3
-
52
-
-
78449243489
-
Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade
-
[PMID: 21074057]
-
Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37: 430-439 [PMID: 21074057 DOI: 10.1053/j.seminoncol.2010.09.005]
-
(2010)
Semin Oncol
, vol.37
, pp. 430-439
-
-
Weber, J.1
-
53
-
-
77954899030
-
Phase i study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
[PMID: 20516446]
-
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175 [PMID: 20516446 DOI: 10.1200/JCO.2009.26.7609]
-
(2010)
J Clin Oncol
, vol.28
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
Powderly, J.D.4
Picus, J.5
Sharfman, W.H.6
Stankevich, E.7
Pons, A.8
Salay, T.M.9
McMiller, T.L.10
Gilson, M.M.11
Wang, C.12
Selby, M.13
Taube, J.M.14
Anders, R.15
Chen, L.16
Korman, A.J.17
Pardoll, D.M.18
Lowy, I.19
Topalian, S.L.20
more..
-
54
-
-
84880715077
-
Survival and long-term follow-up of the phase i trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC)
-
Julie R, Brahmer LH, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, Sankar V, Ahlers CM, Wigginton JM, Kollia G, Gupta AK, Gettinger SN. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). ASCO J ClinOncol 2013; 31: 8030
-
(2013)
ASCO J ClinOncol
, vol.31
, pp. 8030
-
-
Julie, R.1
Brahmer, L.H.2
Antonia, S.J.3
Spigel, D.R.4
Gandhi, L.5
Sequist, L.V.6
Sankar, V.7
Ahlers, C.M.8
Wigginton, J.M.9
Kollia, G.10
Gupta, A.K.11
Gettinger, S.N.12
-
55
-
-
84902206803
-
-
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012). Available from: URL: http://clinicaltrials.gov
-
Study of Nivolumab (BMS-936558) in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or As Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
-
-
-
61
-
-
84904856935
-
Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC)
-
Garon Eea, Balmanoukian A, Hamid O. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). IASLC 15th World Conference on Lung Cancer. Sydney, 2013
-
(2013)
IASLC 15th World Conference on Lung Cancer. Sydney
-
-
Garon Eea1
Balmanoukian, A.2
Hamid, O.3
-
62
-
-
18544380239
-
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
-
[PMID: 12091876]
-
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800 [PMID: 12091876 DOI: 10.1038/nm730]
-
(2002)
Nat Med
, vol.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
Tamura, H.4
Hirano, F.5
Flies, D.B.6
Roche, P.C.7
Lu, J.8
Zhu, G.9
Tamada, K.10
Lennon, V.A.11
Celis, E.12
Chen, L.13
-
63
-
-
84899048777
-
Clinical activity, safety and biomarkers of PD-L1 blocakde in NSCLC: Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1)
-
Soria JC, Cruz C, Bahelda R, Delord JP, Horn L, Herbst RS, Spigel D, Mokatrin A, Fine G, Gettinger S. Clinical activity, safety and biomarkers of PD-L1 blocakde in NSCLC: additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Abstract Search-European Cancer Congress 2013. Available from: URL: http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstractsearch.aspx#
-
Abstract Search-European Cancer Congress 2013
-
-
Soria, J.C.1
Cruz, C.2
Bahelda, R.3
Delord, J.P.4
Horn, L.5
Herbst, R.S.6
Spigel, D.7
Mokatrin, A.8
Fine, G.9
Gettinger, S.10
|